Dublin, June 13, 2024 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Therapeutics - Global Strategic Business Report" report has…
Toronto (www.aktiencheck.de) - Rating-Update:
Die Analysten vom Investmenthaus RBC Capital Markets bestätigen das "sector-perform"-Rating für die Aktie von Vertex Pharmaceuticals Inc.…
Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von BMO Capital Markets:
Die Analysten von BMO Capital Markets stufen die Aktie von Vertex Pharmaceuticals…
Shares of the growing biotech company have doubled in three years.…
Shares of the growing biotech company have doubled in three years.…
The momentum should continue for Eli Lilly, Novo Nordisk, and Vertex Pharmaceuticals.…
Axelerist, an ADDvise Group company, has received an order from Vertex Pharmaceuticals, a global biotechnology company, for the sale and…
Vertex Pharmaceuticals executive sells shares worth over $13k…
Vertex Pharmaceuticals (NDAQ: VRTX) path to becoming a top 20 pharma company with over a $100 billion market cap has…
The biotechs shares dropped following its latest quarterly update, but that shouldnt matter to long-term investors.…
Boston, MA (www.aktiencheck.de) - Rating-Update:
Die Analysten von Leerink Partners wiederholen ihre Empfehlung "outperform" für die Aktie von Vertex Pharmaceuticals Inc.…
Toronto (www.aktiencheck.de) - Rating-Update:
Im Rahmen seiner Einschätzung bleibt Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, bei seiner "sector-perform"-Bewertung für…
Minneapolis (www.aktiencheck.de) - Rating-Update:
Die Analysten von Piper Sandler bewerten die Aktie des US-Biotechkonzerns Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807,…
New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy…
New drugs in development and a lack of significant patent cliffs ahead make this a great pharma stock to buy…
Key earnings movers include Datadog, Palantir and Vertex Pharmaceuticals.…
…
VRTX earnings call for the period ending March 31, 2024.…
Vertex Pharmaceuticals beat first-quarter sales and earnings forecasts, but shares were little moved on the reiterated guidance.…
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.…
Charlotte (www.aktiencheck.de) - Rating-Update:
Die Analysten von BofA Securities bewerten die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol:…
Vertex is broadening its portfolio.…
Vertex is broadening its portfolio.…
Could Vertexs growth story continue?…
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von Evercore ISI stufen die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807,…
New York (www.aktiencheck.de) - Rating-Update:
Die Analysten von H.C. Wainwright & Co. bewerten die Aktie des US-Biotechkonzerns Vertex Pharmaceuticals Inc. (ISIN:…
Vertex Pharmaceuticals $4.9 billion purchase of Alpine Immune Sciences probably wont be the last acquisition of a company focused on…
Vertex Pharmaceuticals $4.9 billion purchase of Alpine Immune Sciences probably wont be the last acquisition of a company focused on…
…
…
During the CNBC Investing Clubs Morning Meeting, Jim Cramer weighed in on the stock moves in Nike, Vertex Pharma and…
The stock hasnt made for a great buy this year, but is Vertex worth investing in for the long run?…
The stock hasnt made for a great buy this year, but is Vertex worth investing in for the long run?…
Kulmbach (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Vertex Pharmaceuticals Inc.…
Große Pharma- und Biotech-Unternehmen sind weiter auf der Suche nach aussichtsreichen Substanzen, um ihre Produktpipeline zu stärken. Der unangefochtene Weltmarktführer…
Große Pharma- und Biotech-Unternehmen sind weiter auf der Suche nach aussichtsreichen Substanzen, um ihre Produktpipeline zu stärken. Der unangefochtene Weltmarktführer…
…
Das biopharmazeutische Unternehmen will die Biotechfirma für rund 4,9 Milliarden Dollar übernehmen. Die Aktien von Alpine legten nachbörslich 36 Prozent…
With the acquisition, Vertex will add Alpines portfolio of protein-based immunotherapies to treat autoimmune and inflammatory diseases.…
Vertex Pharmaceuticals will acquire therapy developer Alpine Immune Sciences for $65 per share, or about $4.9 billion in cash, the…
Vertex Pharmaceuticals to buy Alpine Immune Sciences for $4.9 billion…
What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in…
Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets:
Die Analysten vom Investmenthaus RBC Capital Markets trauen der Aktie von Vertex…
Vertex Pharmaceuticals executive sells shares worth over $100k…
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of…
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this…
…
Vertex Pharmaceuticals already has a fantastic business, and it could get much bigger in the future.…
Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…
Vertex shares have climbed almost 50% over the past year.…